Ziopharm cancer news
Ziopharm refocused and reduced headcount by 4 (19%) to 17, with the cuts in preclinical and clinical development. The company plans to focus on IV palifosfamide ( ZIO-201). The IV formulation of the bi-functional alkylator is in the ongoing Phase II PICASSO trial in combination with doxorubicin to treat soft-tissue sarcoma (STS). Ziopharm hopes to begin Phase III testing of IV palifosfamide in combination with doxorubicin for first- and second-line treatment of soft-tissue sarcoma in 1H10. Ziopharm will not begin new trials of its other cancer programs until the company is able to secure a partner or additional funds. The IV formulation of darinaparsin, an organic arsenic, is in Phase II testing for primary liver cancer, advanced myeloma and other hematological malignancies. ...